Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has issued an update.
Hemogenyx Pharmaceuticals announced that the Data Safety Monitoring Board has approved the continuation of its Phase I clinical trial for HG-CT-1, a CAR-T therapy for acute myeloid leukemia, allowing dose escalation and the start of pediatric recruitment. This milestone signifies a de-risking step in the therapy’s development, potentially enhancing its efficacy and paving the way for broader clinical validation, which could positively impact the company’s market position and investor interest.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 124,365
Technical Sentiment Signal: Buy
Current Market Cap: £46.54M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.